Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates
Quarterly Performance: Sutro Biopharma reported a quarterly loss of $0.89 per share, slightly worse than the expected loss of $0.86, with revenues of $14 million exceeding estimates by 34.11%. The company has seen mixed earnings estimate revisions and currently holds a Zacks Rank #3 (Hold).
Market Outlook: Despite underperforming the market with a 27.2% decline this year, the stock's future performance will depend on management's commentary and changes in earnings expectations, as well as the overall industry outlook, which is currently favorable within the top 26% of Zacks industries.
Trade with 70% Backtested Accuracy
Analyst Views on APRE
About APRE
About the author
Aprea Therapeutics Closes $30 Million Oversubscribed Financing
- Successful Financing: Aprea Therapeutics closed an oversubscribed $30 million private placement on March 31, 2026, with proceeds allocated for general corporate purposes and R&D expenses, thereby enhancing financial flexibility to support its clinical projects.
- Clinical Trial Progress: The company's lead candidate APR-1051 is undergoing a Phase 1 trial for advanced solid tumors, showing promising clinical activity, with further updates expected in Q2 2026, which could drive stock price appreciation.
- Analyst Rating Maintained: Wedbush analyst Robert Driscoll reaffirmed an Outperform rating for Aprea with a 12-month price target of $7, reflecting market confidence in its product potential and likely attracting more investor interest.
- Cash Flow Status: As of December 31, 2025, Aprea reported cash and cash equivalents of $14.6 million, and with the recent financing, projected a cash runway through Q1 2027, providing a safeguard for the company's future development.
Aprea Therapeutics Reports Significant Tumor Shrinkage in Early Trial
- Significant Tumor Reduction: Aprea Therapeutics reported a 50% tumor shrinkage in a patient from its early-stage trial of APR-1051, alongside a notable decline in the tumor biomarker CA-125, indicating the drug's potential therapeutic impact and strengthening the company's market outlook.
- Mild Side Effects: The patient experienced only low-grade treatment-emergent adverse effects and continued treatment, suggesting good tolerability of APR-1051, which provides positive safety data for future clinical trials.
- Follow-Up Assessment Plans: The company is eyeing confirmation of the partial responses observed in both patients through subsequent imaging assessments, with further updates expected in Q2 2026, which could positively influence investor confidence.
- Positive Market Reaction: Following the announcement, Aprea's shares surged 15%, with all analysts covering the stock rating it as 'Buy' or higher, and a 12-month average price target of $5.33, representing a potential upside of approximately 788%, reflecting optimistic market sentiment regarding its future performance.
APREA THERAPEUTICS EXPANDS GLOBAL PATENT PORTFOLIO IN DNA DAMAGE RESPONSE (DDR) CANCER TREATMENTS, FOSTERING PIPELINE EXPANSION
Company Overview: Aprea Therapeutics is enhancing its global patent portfolio, particularly in the area of DNA damage response (DDR) cancer therapeutics.
Strategic Focus: The company is paving the way for potential growth in the pipeline of its cancer therapies, indicating a commitment to advancing treatment options.
Aprea Therapeutics Appoints New Chief Medical Advisor
- New Chief Medical Advisor: Aprea Therapeutics has appointed Dr. Eugene Kennedy as Chief Medical Advisor, aiming to strengthen the company's clinical leadership in advancing the dose-escalation study of the WEE1 inhibitor APR-1051 in patients with advanced solid tumors.
- Clinical Trial Progress: Dr. Kennedy's appointment coincides with the company's recent early clinical proof-of-concept success in its ongoing Phase 1 dose-escalation study, which is expected to optimize patient selection and advance the DNA damage response program.
- Extensive Industry Experience: With over 20 years of experience in oncology clinical development and regulatory strategy, Dr. Kennedy has held senior positions in multiple biotechnology companies, which is anticipated to provide critical support for Aprea's clinical decision-making.
- Aligned Strategic Goals: Dr. Kennedy expressed alignment with Aprea's strategy to leverage DNA damage response inhibitors to transform treatment approaches for difficult-to-treat cancers, further advancing the company's clinical asset development.
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
Preclinical and Clinical Findings: Aprea Therapeutics has reported promising preclinical data for APR-1051, a WEE1 inhibitor, showing strong anti-tumor effects in HPV+ head and neck squamous cell carcinoma (HNSCC) models, particularly when combined with anti–PD-1 therapies. Initial clinical results from a Phase 1 trial indicate early disease control in an HPV+ patient.
Future Development Plans: The company is progressing with the ACESOT-1051 trial, which includes dose escalation and further evaluation of APR-1051 in combination with checkpoint inhibitors to enhance treatment outcomes for patients with HPV-associated cancers.
HC Wainwright & Co. Reiterates Buy on Aprea Therapeutics, Maintains $20 Price Target
Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.
Community of Traders: The platform boasts a community of over 10,000 serious traders who benefit from exclusive stories and accurate market intelligence provided by Benzinga reporters.
Aprea Therapeutics Closes $30 Million Oversubscribed Financing
- Successful Financing: Aprea Therapeutics closed an oversubscribed $30 million private placement on March 31, 2026, with proceeds allocated for general corporate purposes and R&D expenses, thereby enhancing financial flexibility to support its clinical projects.
- Clinical Trial Progress: The company's lead candidate APR-1051 is undergoing a Phase 1 trial for advanced solid tumors, showing promising clinical activity, with further updates expected in Q2 2026, which could drive stock price appreciation.
- Analyst Rating Maintained: Wedbush analyst Robert Driscoll reaffirmed an Outperform rating for Aprea with a 12-month price target of $7, reflecting market confidence in its product potential and likely attracting more investor interest.
- Cash Flow Status: As of December 31, 2025, Aprea reported cash and cash equivalents of $14.6 million, and with the recent financing, projected a cash runway through Q1 2027, providing a safeguard for the company's future development.
Aprea Therapeutics Reports Significant Tumor Shrinkage in Early Trial
- Significant Tumor Reduction: Aprea Therapeutics reported a 50% tumor shrinkage in a patient from its early-stage trial of APR-1051, alongside a notable decline in the tumor biomarker CA-125, indicating the drug's potential therapeutic impact and strengthening the company's market outlook.
- Mild Side Effects: The patient experienced only low-grade treatment-emergent adverse effects and continued treatment, suggesting good tolerability of APR-1051, which provides positive safety data for future clinical trials.
- Follow-Up Assessment Plans: The company is eyeing confirmation of the partial responses observed in both patients through subsequent imaging assessments, with further updates expected in Q2 2026, which could positively influence investor confidence.
- Positive Market Reaction: Following the announcement, Aprea's shares surged 15%, with all analysts covering the stock rating it as 'Buy' or higher, and a 12-month average price target of $5.33, representing a potential upside of approximately 788%, reflecting optimistic market sentiment regarding its future performance.
APREA THERAPEUTICS EXPANDS GLOBAL PATENT PORTFOLIO IN DNA DAMAGE RESPONSE (DDR) CANCER TREATMENTS, FOSTERING PIPELINE EXPANSION
Company Overview: Aprea Therapeutics is enhancing its global patent portfolio, particularly in the area of DNA damage response (DDR) cancer therapeutics.
Strategic Focus: The company is paving the way for potential growth in the pipeline of its cancer therapies, indicating a commitment to advancing treatment options.
Aprea Therapeutics Appoints New Chief Medical Advisor
- New Chief Medical Advisor: Aprea Therapeutics has appointed Dr. Eugene Kennedy as Chief Medical Advisor, aiming to strengthen the company's clinical leadership in advancing the dose-escalation study of the WEE1 inhibitor APR-1051 in patients with advanced solid tumors.
- Clinical Trial Progress: Dr. Kennedy's appointment coincides with the company's recent early clinical proof-of-concept success in its ongoing Phase 1 dose-escalation study, which is expected to optimize patient selection and advance the DNA damage response program.
- Extensive Industry Experience: With over 20 years of experience in oncology clinical development and regulatory strategy, Dr. Kennedy has held senior positions in multiple biotechnology companies, which is anticipated to provide critical support for Aprea's clinical decision-making.
- Aligned Strategic Goals: Dr. Kennedy expressed alignment with Aprea's strategy to leverage DNA damage response inhibitors to transform treatment approaches for difficult-to-treat cancers, further advancing the company's clinical asset development.
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
Preclinical and Clinical Findings: Aprea Therapeutics has reported promising preclinical data for APR-1051, a WEE1 inhibitor, showing strong anti-tumor effects in HPV+ head and neck squamous cell carcinoma (HNSCC) models, particularly when combined with anti–PD-1 therapies. Initial clinical results from a Phase 1 trial indicate early disease control in an HPV+ patient.
Future Development Plans: The company is progressing with the ACESOT-1051 trial, which includes dose escalation and further evaluation of APR-1051 in combination with checkpoint inhibitors to enhance treatment outcomes for patients with HPV-associated cancers.
HC Wainwright & Co. Reiterates Buy on Aprea Therapeutics, Maintains $20 Price Target
Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.
Community of Traders: The platform boasts a community of over 10,000 serious traders who benefit from exclusive stories and accurate market intelligence provided by Benzinga reporters.
